to launch cancer drug Tykerb in India
7 November 2007
GlaxoSmithKline's is set to launch the breast-cancer drug Tykerb in India by sometime
early next year.
company is reported to be lining up critical care and cardio-vascular drugs for
the Indian market through two, yet-to-be formalised, in-licensing deals.
to Dr Hasit Joshipura, vice president (South-Asia) and managing director (India)
of GlaxoSmithKline Pharmaceuticals, the company is in the process of signing deals
on the critical care and cardiovascular drugs, and should hopefully be ready with
an announcement by the end of the year. One of these drugs is reportedly a patented
strategy is unique to the Indian market. GSK has eight in-licensing deals in place,
which reportedly accounted for around 20 per cent of the company's growth last
year. GSK previously brought in Eisai's anti-ulcer drug Parit, and Novartis' anti-fungal
drug Terbenafine through the in-licensing route.
oncology product Tykerb goes by the generic name is lapatinib. GSK reportedly
has received approval to market it, and is waiting for site registration, basis
which it is confident of launching the drug in India sometime in the first two
quarters of 2008. Also lined up for launch is GSK's rotavirus vaccine, related
to gastroenteritis, which will come to the Indian market almost simultaneously.
six-in-one combination vaccine - Infanrix hexa, which immunises against six diseases,
is also reportedly ready to be rolled-out during the same period, and will be
one of the products from the yet-to-be signed in-licensing deals.
break-through cervical cancer vaccine is reportedly coming to India by 2009.
to Dr Joshipura, Tykerb is for patients who had failed Herceptin treatment, a
medicine from Roche, and is for a very clearly defined patient group.
reports on Glaxo SmithKline India Ltd
reports on Pharmaceuticals
reports on Healthcare
reports on Marketing